Allarity Therapeutics, Inc. (ALLR)
(Delayed Data from NSDQ)
$0.18 USD
+0.01 (3.51%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $0.18 0.00 (-1.59%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Allarity Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 2 | 20 | 0 | -99,999 |
Receivables | 1 | 1 | 1 | 1 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 1 | 2 | 1 | 1 | NA |
Total Current Assets | 2 | 5 | 21 | 2 | NA |
Net Property & Equipment | 0 | 0 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 1 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 10 | 10 | 28 | 30 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 12 | 15 | 50 | 33 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 8 | 6 | 1 | 2 | NA |
Current Portion Long-Term Debt | 0 | 3 | 0 | 1 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 1 | 2 | 9 | 2 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 4 | 0 | 11 | 0 | NA |
Total Current Liabilities | 14 | 11 | 21 | 6 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 2 | 2 | NA |
Convertible Debt | 0 | 1 | 1 | 1 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 7 | 0 | NA |
Minority Interest (Liabilities) | 0 | 2 | 1 | 0 | NA |
Total Liabilities | 15 | 15 | 31 | 9 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 2 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 1 | 0 | NA |
Capital Surplus | 90 | 83 | 84 | 62 | NA |
Retained Earnings | -94 | -83 | -66 | -40 | NA |
Other Equity | 0 | -1 | -1 | 1 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | -3 | 0 | 18 | 24 | NA |
Total Liabilities & Shareholder's Equity | 12 | 15 | 50 | 33 | NA |
Total Common Equity | -4 | 0 | 18 | 24 | 0 |
Shares Outstanding | 0.20 | 0.00 | NA | NA | NA |
Book Value Per Share | -22.45 | -0.11 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Allarity Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 19 | 0 | 0 | 1 | 0 |
Receivables | 2 | 1 | 1 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 2 |
Total Current Assets | 21 | 2 | 2 | 4 | 4 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 10 | 10 | 10 | 9 | 10 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 31 | 12 | 12 | 14 | 13 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 11 | 8 | 6 | 8 |
Current Portion Long-Term Debt | 1 | 3 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 2 | 1 | 1 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 3 | 4 | 8 | 2 |
Total Current Liabilities | 11 | 18 | 14 | 16 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 1 | 1 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 11 | 18 | 15 | 17 | 14 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 2 | 2 | 2 | 6 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 120 | 91 | 90 | 88 | 83 |
Retained Earnings | -100 | -98 | -94 | -93 | -88 |
Other Equity | -1 | 0 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 20 | -6 | -3 | -3 | -1 |
Total Liabilities & Shareholder's Equity | 31 | 12 | 12 | 14 | 13 |
Total Common Equity | 20 | -8 | -4 | -5 | -6 |
Shares Outstanding | 17.60 | 2.30 | 0.20 | 0.20 | 0.00 |
Book Value Per Share | 1.13 | -3.47 | -22.45 | -25.60 | -6.36 |